Overview

An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To investigate efficacy, safety and tolerability of Celecoxib in patients with posttraumatic pain for the duration of 8 days.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Celecoxib